DUBLIN--(BUSINESS WIRE)--The "Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend affecting this market is increase in global awareness about cancer treatments. Awareness about cancer treatments and cancer related issues across the US has increased primarily because of the continuing efforts of different organizations.
According to the report, one driver influencing this market is the rising number of patients opting for chemotherapy. The increasing use of chemotherapy and its associated risks in affecting immunity due to neutropenia, coupled with growing patient population, generate the demand for CIN therapeutics.
Further, the report states that one challenge affecting this market is the high cost of treatment. Through chemotherapy is an effective treatment for cancer, the risks associated with it, such as CIN, can lead to increase in hospital visits and longer hospital stays.
- Intas Pharmaceuticals
- Partner Therapeutics
- Teva Pharmaceuticals Industries
Key Topics Covered
1. Executive Summary
2. Scope of the Report
3. Research Methodology
4. Market Landscape
5. Market Sizing
6. Five Forces Analysis
7. Market Segmentation by Procedure
8. Customer Landscape
9. Regional Landscape
10. Decision Framework
11. Drivers and Challenges
12. Market Trends
13. Vendor Landscape
14. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/l63fmx/global_outlook?w=4